ExodusPoint Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

ExodusPoint Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-24,612	Closed	-$173K	–	1454
2024 Q3	$173K	Buy	+24,612	New	+$179K	﹤0.01%	1470
2022 Q2	–	Sell	-39,636	Closed	-$519K	–	1888
2022 Q1	$519K	Buy	39,636 +7,856	+25%	+$115K	0.01%	1487
2021 Q4	$559K	Sell	31,780 -16,486	-34%	-$330K	0.01%	1340
2021 Q3	$1.05M	Buy	48,266 +44,560	+1,202%	+$1.14M	0.01%	1001
2021 Q2	$130K	Buy	+3,706	New	+$200K	﹤0.01%	2094
2021 Q1	–	Sell	-1,211	Closed	-$131K	–	2076
2020 Q4	$131K	Buy	+1,211	New	+$150K	﹤0.01%	1800
2020 Q3	–	Sell	-1,038	Closed	-$217K	–	1697
2020 Q2	$217K	Buy	+1,038	New	+$184K	0.01%	1477

Other funds holding ADVM

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PWA

Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ExodusPoint Capital Management's ADVM Position: Q4 2024 in Review

ExodusPoint Capital Management sold out of Adverum Biotechnologies (ADVM) in Q4 2024, closing a stake of 24,612 shares — an estimated $173K sold.

ExodusPoint Capital Management first reported a position in ADVM in Q2 2020 and held it in 7 quarters. The position peaked at $1.05M in Q3 2021. 69 funds tracked by Wall St. Rank hold ADVM as of Q4 2024.

ExodusPoint Capital Management reported no remaining Adverum Biotechnologies position as of Q4 2024 after selling out during the quarter.
ExodusPoint Capital Management sold 24,612 Adverum Biotechnologies shares in Q4 2024, an estimated $173K.
ExodusPoint Capital Management first reported a position in Adverum Biotechnologies in Q2 2020 and held it in 7 quarters.
ExodusPoint Capital Management's Adverum Biotechnologies position peaked at $1.05M in Q3 2021.
69 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2024.

Based on ExodusPoint Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.